NARI Earnings

NARI reported its FY2024Q3 earnings on 2024-10-28, showcasing a revenue of 153.39M against an estimate of 150.67M, resulting in a 1.8% surprise. The EPS was -0.13, surpassing the expected -0.12 by -8.33% . The stock experienced a 15.55% price change on the earnings day and a 14.97% change over the next five days, reflecting market reactions to the results.

Following NARI's FY2024Q3 earnings announcement on 2024-10-28, the stock price moved by 15.55% on the day of the release. Over the subsequent five days, it saw a 14.97% change. Historically, NARI's stock price tends to shift by an average of +1.83% in the 10 days leading up to earnings and +1.86% in the 10 days following, providing insight into potential market.

For 2024/Q4, analysts estimate NARI’s annual revenue to reach 160.70M, while the EPS is projected at 0.01. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between NARI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2024 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NARI's stock price typically moves by +1.83% in the 10 days before its earnings and +1.86% in the 10 days after. For the upcoming 2024/Q4 earnings, analysts expect an EPS of 0.01 and revenue of 160.70M.

The earnings call presents mixed signals. Financial performance shows strong revenue growth but also increased operating losses, which is concerning. The Q&A section reveals stable market health and growth potential, but management's vague responses on certain topics may raise investor concerns. The lack of a shareholder return plan and declining gross margins also contribute to a neutral outlook. However, the raised annual revenue guidance and robust growth in emerging therapies offer positive aspects, balancing the negative elements. Given the company's market cap, the stock price is likely to remain stable over the next two weeks.